Liberale versus restriktive EK-Transfusion

Similar documents
Blood transfusions in ICU: double-edged sword. Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal

Transfusion triggers in acute coronary syndromes: The MINT trial

Patient Blood Management: Enough is Enough

Science Evidence Cost

Transfusion Indications: Update in 2019

Transfusions in Acute Care Too Little?

Transfusion & Mortality. Philippe Van der Linden MD, PhD

Red Cell Transfusion triggers: A moving target When, who, and how much?

HB TRIGGER & SINGLE UNITS

Blood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18

Clinical Controversies in Perioperative Medicine

efs.sante.fr The best blood donor and blood product for each patient: an evolving role for haemovigilance? Pierre Tiberghien Etablissement Français du

Supplementary Online Content

Goal Directed Therapy : Liberal vs Restrictive Transfusion.. Syafri Kamsul Arif

Clinical Controversies in Perioperative Medicine!

Blood Transfusion Project. Reducing Transfusion in the MARCQI Population

EVIDENCE BASED RED CELL TRANSFUSION. Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System

BONE MARROW PERIPHERAL BLOOD Erythrocyte

SESSION 5 2:20 3:35 pm

Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto

Guidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct

Advances in Transfusion and Blood Conservation

Alternatives to RBC Transfusion:

Alternatives to RBC Transfusion: Erythropoietin and beyond

Early Management of the Patient with Acute GI Bleeding

DECLARATION OF CONFLICT OF INTEREST. None declared

Supplementary Online Content

Catheter-based mitral valve repair MitraClip System

Presented by: Indah Dwi Pratiwi

Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Anaemia in the ICU: Is there an alternative to using blood transfusion?

Blood transfusions in sepsis, the elderly and patients with TBI

Transfusion for the sickest ICU patients: Are there unanswered questions?

Ischemic Heart Disease: The 5 Most Important Trials in the Last Year

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

Dr Tushar Mahambrey. Consu ltant Critical Care Med icine & Anaesthetics St Helens and Knowsley N H S teaching hospitals Liverpool

Fasting or non fasting?

A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions

CARDIOVASCULAR RISK and NSAIDs

Carotid Artery Stenosis

Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto

Year in Review: Critical Care Medicine

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

Red blood cell transfusions Risks, benefits, and surprises

Utilities and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials. Cardiovascular Research Foundation Columbia University Medical Center

Supplementary Online Content

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL

Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE

Which Test When? Avoid the Stress of Stress Testing. Marc Newell, MD, FACC, FSCCT Minneapolis Heart Institute

Risk Factors and Management of Acute Renal Injury in Cardiac Surgery

MODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE. Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands

Iron depletion in frequently donating whole blood donors. B. Mayer, H. Radtke

Overview of session. Blood transfusions in advanced disease 3/21/18. Why am I interested in blood transfusions?

Drug induced hemolysis: transfusion management Interactive case study

Patient Blood Management: At the Forefront of Quality and Value in Healthcare

High Sensitivity Troponin Improves Management. But Not Yet

Valvular Intervention

Optimal lenght of DAPT in different clinical scenarios

Red blood cell transfusions in the PICU: What & When

DECLARATION OF CONFLICT OF INTEREST

Approach to Multi Vessel disease with STEMI

e Corrado Tamburino, MD, PhD

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

OXYGENATION AND ACID- BASE EVALUATION. Chapter 1

Chest diseases Hospital Laboratory Hematology Practice guidelines

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

No Excellence Without Evidence: The Therapeutic Use of Oxygen

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization.

Treatment Strategies For Patients with Peripheral Artery Disease

Medical Therapy for Peripheral Artery Disease

Overview of Trasradial Approach for Coronary Angiography and Intervention. A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC

Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD

Module G: Oxygen Transport. Oxygen Transport. Dissolved Oxygen. Combined Oxygen. Topics to Cover

TACO Est ce que cette complication transfusionnelle peut être prédite et prévenue?

Preparing for Patients at High Risk of Transfusion

Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD

FFR in Multivessel Disease

Use of Biomarkers for Detection of Acute Myocardial Infarction

Transfusion Triggers. Richard Soutar January 2012

Acute Coronary Syndrome. Sonny Achtchi, DO

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Blood Transfusion Guidelines in Clinical Practice

ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

Evidence-based Decision Making for Transfusion Practices. Moderator: John Fargo, DO Speaker: William Savage, MD PhD

Dr Marina Karakantza Consultant Haematologist, NHSBT

Austrian Society for Blood Transfusion and Regenerative Medicine. Klagenfurt - May 2015

Clopidogrel Use in ACS and PCI: Clinical Trial Update

On Referral to our Unit

Controversies in Transfusion Medicine

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

Fractional Flow Reserve: Review of the latest data

Early Management of the Patient with Acute GI Bleeding

RHU ivasc: CONSTANCES et la recherche cardiovasculaire. Ph.Gabriel STEG DHU FIRE Hôpital Bichat; AP-HP INSERM U1148 Université Paris Diderot

DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

Top-5 Recommendations SMARTER MEDICINE IN THE HOSPITAL. Prof. Christoph A. Meier et al. Annual Congress SSMIG Basel, May 25 th 2016

Anticoagulation Therapy in LTC

Transcription:

SWISSTRANSFUSION 2016 Thursday, August 25, 2016; 11:00 11:30 am Liberale versus restriktive EK-Transfusion Reto Schüpbach Dokumentenname Datum Seite 0

Pull out, you hit the artery! www.pinterest.com Dokumentenname Datum Seite 1

Fundamentalism and religion IS: Flag Dokumentenname Datum Seite 2

Red cell transfusion Religion? + - Anemia is a disease(?) - Performance increases with hemoglobin - Severe anemia is lethal - - Transfusion is costly - Transfusion kills Dokumentenname Datum Seite 3

Severe anemia can result in death Hb 10-20g/L: Mortality 100% Hb 20-30g/L: Mortality 54% Hb 30-40g/L: Mortality 27% Hb 40-50g/L: Mortality 34% Hb 50-60g/L: Mortality 9% Hb 70-80g/L: Mortality <1% Source: Data base APACHEII Dokumentenname Datum Seite 4

damage Harm caused by anemia 20 40 60 80 normal range Hb [g/l] Dokumentenname Datum Seite 5

Compensatory mechanisms for anemia O 2 delivery - DO2 = Arterial oxygen content x Cardiac Output x 10 [Hb x 1.39 ml/gm x Sat.] + [PaO2 x 0.0031] Additional complex adaptions - Matching of O 2 affinity in hemoglobin, myoglobin and mitochondrial proteins - Alteration in rheology - Alteration of flow profile (no TC marginalization) - Alteration in endothelial adherence Dokumentenname Datum Seite 6

damage Harm caused by anemia 20 40 60 80 normal range Hb [g/l] Dokumentenname Datum Seite 7

Severe anemia is harmful BMJ VOLUME 327 20 27 DECEMBER 2003 Dokumentenname Datum Seite 8

damage Is transfusion harmful Hb Dokumentenname Datum Seite 9

Harm caused by transfusion (incidence) Ann Intern Med. 2012;157:49-58. Dokumentenname Datum Seite 10

Nevertheless: The product matters Lacroix, NEJM 2015 Dokumentenname Datum Seite 11

damage Between liberal and restrictive, there is an optimum Just right! Hb Dokumentenname Datum Seite 12

Leverage the sweet spot Quality of the product Quantity of the products Safety of the product Ability to compensate for anemia Coping with transfusion Dokumentenname Datum Seite 13

Focus #1: Patient with risk factors Do you transfuse a patient with cardiovascular risk factors undergoing surgery? Dokumentenname Datum Seite 14

Focus #1: Patient with risk factors What about a patient potentially not able to increase cardiac output? DO2 = Arterial oxygen content x Cardiac Output x 10 Dokumentenname Datum Seite 15

Patients with risk factors undergoing surgery Dokumentenname Datum Seite 16

Hip fracture >50 y of age >CV risk or history Randomization if Hb < 10g/dL Liberal (n=1007) Restrictive (n=1009) Maintain Hb > 10g/dL Outcome: Combined: Death or inability to walk 60 days post op Trigger Hb < 8g/dL or symptoms Dokumentenname Datum Seite 17

Transfusion among stable high risk patients: Good Job! Dokumentenname Datum Seite 18

But poor results! Dokumentenname Datum Seite 19

How to stimulate POWER? Dokumentenname Datum Seite 20

Driving Power? 100% 7 90% 6 80% 70% 5 60% 4 50% 3 40% Sample size Between group difference Homogeneity 30% 2 20% 1 10% 0 0% Category 1 Category 2 Category 1 Category 2 Series 2 Series 1 Dokumentenname Datum Seite 21

Transfusion in stable high-risk surgical patients: But poor results! http://www.stat.ubc.ca/~rollin/stats/ssize/ Dokumentenname Datum Seite 22

Transfusion in stable high-risk surgical patients: But poor results! Power 16%; für 80% wären pro Gruppe 8768 Patienten notwendig Dokumentenname Datum Seite 23

In stable patients, 80g/L is the sweet spot Trigger at < 80g/L safe However symptomatic patients have been transfused More bleeding at lower trigger Dokumentenname Datum Seite 24

Focus #2: Cardiac surgery Triggers for patients undergoing cardiac surgery? Dokumentenname Datum Seite 25

Cardiac surgery? Dokumentenname Datum Seite 26

>16 y of age No emergency cardiac surgery Randomization if Hb < 9g/dL Liberal (n=1000) Trigger Hb < 9 g/dl Restrictive (n=1003) Trigger Hb < 7.5 g/dl Outcome: Infection or ischemic event within 3 months Dokumentenname Datum Seite 27

Transfusion in cardiac surgery Dokumentenname Datum Seite 28

Transfusion in cardiac surgery Dokumentenname Datum Seite 29

What about secondary endpoints? (=mortality!) Dokumentenname Datum Seite 30

Did we get to the of bottom it? Trigger of < 75g/L not inferior to 90g/L Potentially more death in restrictive transfusion group No shunt patients Dokumentenname Datum Seite 31

Focus #3: Cardiac ischemia What is safe in patients with myocardial infarction? Dokumentenname Datum Seite 32

Transfusion in patients with myocardial infarction (Less is more) Chatterjee S, JAMA, 2013, 173, 2, 132-9 Dokumentenname Datum Seite 33

Problems with case control data Salisbury AC, JACC 2014, 64; 8, 811-9 Dokumentenname Datum Seite 34

Challanges in case control data Salisbury AC, JACC 2014, 64; 8, 811-9 Dokumentenname Datum Seite 35

Adjusted models Hb range Unadj. Adj. Hb < 7g/dL 0.52 (0.32-0.84) 0.59 (0.31-1.11) Hb 7-8.9g/dL 0.73 (0.6-0.9) 0.65 (0.51-0.82) Hb 9-10.9g/dL 0.97 (0.64-1.47) 0.74 (0.47-1.16) Hb > 11g/dL 6.28 (2.12-18.59) 1.97 (0.42-9.24) Salisbury AC, JACC 2014, 64; 8, 811-9 Dokumentenname Datum Seite 36

Potential benefit for symptomatic patients Carson JL; Am Heart J. 2013 Jun;165(6):964-971 Dokumentenname Datum Seite 37

Transfusion strategy in myocardial infarction Restrictive triggers established (less is more; JAMA2013) However bias might drive safety Propensity analyses in databases of patients with MI favor of more liberal triggers Small studies support trigger of > 100g/L before catheter therapy Dokumentenname Datum Seite 38

damage Individual safety profiles required? 40 70 100 Hb [g/l] Dokumentenname Datum Seite 39

What about long term risk (FOCUS) Dokumentenname Datum Seite 40

Dokumentenname Datum Seite 41

Cost efficiency? Cost / Unit: $ 320 liberal: restrictive: P value Transfusionen $ 713 $ 479 <0.001 Spital $18 059 $17 762 n.s. Spital / survival $18 540 $18 540 n.s. Gavin, JM, NEJM 2015; 372, 11; 997-1008 Dokumentenname Datum Seite 42

Est ultra! Villanueva NEJM, 2013 Dokumentenname Datum Seite 43

Severe acute upper GI bleeding n=921 (screened 1610) Liberal (n=460) Trigger Hb < 9 g/dl Restrictive (n=461) Trigger Hb < 7 g/dl Outcome: Death within 45 days Villanueva NEJM, 2013 Dokumentenname Datum Seite 44

Est ultra! Villanueva NEJM, 2013 Dokumentenname Datum Seite 45

damage Optimal trigger Hb Dokumentenname Datum Seite 46

Conclusion: Triggers are individual parameters and depend on performance Aim for the sweet spot Transfusion of erythrocytes carry few risks Patients at risk for cardiac ischemia and unable to compensate for anemia should be transfused more liberal Patients with activated endothelium (e.g. hepatopathy) should be transfused with caution Cost saving by just reducing transfusion policy is challenging Dokumentenname Datum Seite 47

Thank you for your attention! reto.schuepbach@usz.ch Dokumentenname Datum Seite 48

Forest plot of myocardial infarctions in low risk of bias trials Power 35% Holst LB, BMJ 2015; 350:h1354 Dokumentenname Datum Seite 49